Comprehensive Regulatory Certifications Empowering Global Reach

At Taj Pharma, our Oral Solid Dosage (OSD) and External Preparations plant is meticulously built on globally recognized compliance frameworks, enabling seamless access to highly regulated and semi-regulated pharmaceutical markets. Through multi-certification integration, we meet and exceed international standards, validating our capability to manufacture safe, effective, and globally compliant medicines.

WHO-GMP: The Foundation of Pharmaceutical Quality Assurance

Our plant operates under strict WHO-GMP (World Health Organization – Good Manufacturing Practices) guidelines. This certification serves as a quality backbone, ensuring:

WHO-GMP certification granted to Taj Pharma's formulations manufacturing plant
WHO-GMP certification
  • Validated manufacturing processes
  • Microbial and contamination control
  • Controlled environments for OSD and topical preparations
  • Robust documentation and SOP adherence
  • Competency-based personnel training programs

We comply with WHO-GMP standards across tablets, capsules, powders, and external forms such as creams, ointments, and gels. This certification not only secures market entry to developing countries but is crucial for WHO Prequalification and UN procurement channels.

WHO-GMP: The Foundation of Pharmaceutical Quality Assurance

At Taj Pharma, our unwavering commitment to quality begins with adherence to the WHO-GMP (World Health Organization – Good Manufacturing Practices) framework—a globally accepted benchmark that governs every aspect of pharmaceutical manufacturing. This certification is not just a compliance milestone; it is the core architecture of quality assurance embedded across our Oral Solid Dosage (OSD) and External Preparations plant.

The WHO-GMP guidelines ensure that products are consistently manufactured and controlled to the quality standards appropriate for their intended use and as required by the marketing authorization. This includes a holistic approach spanning from raw material sourcing to final product release. Our WHO-GMP implementation encompasses the following essential pillars:

Validated Manufacturing Processes

We utilize process validation protocols that establish documented evidence confirming each production step—be it blending, granulation, compression, coating, or packaging—is capable of reliably delivering a product that meets its predetermined specifications and quality attributes. This includes:

  • Installation Qualification (IQ)
  • Operational Qualification (OQ)
  • Performance Qualification (PQ)
  • Process Performance Qualification (PPQ)

Each manufacturing batch undergoes stringent in-process checks and post-production evaluations to ensure lot-to-lot consistency, minimizing variability and safeguarding patient outcomes.

Microbial and Contamination Control

The prevention of microbial and cross-contamination is non-negotiable under WHO-GMP. Our plant is designed with segregated zones for handling different dosage forms, supported by:

  • Air Handling Units (AHUs) with HEPA filtration
  • Differential pressure gradients
  • Regular air, surface, and personnel monitoring
  • Sanitation schedules and validated disinfectants

Topical preparations, in particular, demand tight microbial controls due to their direct application to skin or mucosal surfaces. We adhere to defined bioburden limits, conduct preservative efficacy testing (PET), and follow cleanroom classification based on ISO standards.

Controlled Environments for OSD and Topical Preparations

Our facility is designed according to cGMP-compliant architectural layouts with unidirectional process flows, minimizing the risk of mix-ups and contamination. Environmental parameters are continuously monitored via:

  • BMS (Building Management Systems)
  • Temperature and humidity sensors
  • Automated alarm-based deviations
  • Real-time data logging and validation

Separate HVAC systems are used for different product lines—beta-lactam, hormonal, non-beta-lactam OSD, and external preparations—ensuring product-specific containment and control.

Robust Documentation and SOP Adherence

WHO-GMP places immense importance on documentation integrity. Our Quality Management System (QMS) maintains:

  • Master Formula Records (MFRs)
  • Batch Manufacturing Records (BMRs)
  • Standard Operating Procedures (SOPs)
  • Logbooks and equipment usage records
  • Deviation, CAPA, and change control registers

Each document is version-controlled, authorized, and periodically reviewed. The use of 21 CFR Part 11 compliant electronic systems ensures data integrity (ALCOA+ principles), traceability, and audit readiness at all times.

Competency-Based Personnel Training Programs

Personnel competence is a cornerstone of WHO-GMP compliance. We implement a structured training calendar covering:

  • GMP principles
  • SOP-specific job functions
  • Safety and hygiene protocols
  • Aseptic techniques (for sterile areas)
  • Deviation handling and documentation practices

All training activities are recorded, evaluated, and periodically refreshed to ensure a workforce that is not only qualified but also aware of evolving regulatory requirements. Every staff member, from manufacturing operators to quality assurance personnel, undergoes initial qualification and on-the-job assessments.


WHO-GMP certification for Taj Pharma’s OSD and External Preparations Plant is a declaration of our readiness to meet global therapeutic demands with absolute confidence in product quality, regulatory alignment, and patient safety. It is the foundation of our pharmaceutical credibility, allowing us to cater to diverse markets and exceed the expectations of health authorities and patients worldwide.

PIC/S GMP: Streamlined Global Regulatory Acceptance

Taj Pharma’s plant is aligned with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) guidelines, enabling harmonized inspection standards recognized by over 50 regulatory authorities including:

  • Thailand (FDA THAI) / Malaysia (NPRA)
  • EMA (EU)
  • MHRA (UK)
  • TGA (Australia)
  • Health Canada

Thailand FDA-GMP Certification: Strengthening Southeast Asian Market Presence

PICs GMP Certificate Taj Pharma
PICs GMP Certificate Taj Pharma

Taj Pharma has successfully obtained GMP certification from the Thailand Food and Drug Administration (FDA Thai)—a significant regulatory milestone that reinforces our commitment to delivering world-class pharmaceutical products to Southeast Asia. The Thailand FDA is recognized for its rigorous inspection standards, aligned closely with ASEAN Common Technical Requirements (ACTR) and international GMP benchmarks, ensuring that only the highest quality manufacturers are granted approval.

This certification underscores several key aspects of our manufacturing excellence:

  • Facility Readiness and Compliance: Our plant underwent thorough inspections by Thai regulators, covering facility layout, hygiene standards, process validation, and documentation practices tailored to Thailand’s pharmaceutical laws.
  • Product-Specific Evaluation: FDA Thai’s approval process involves reviewing individual product dossiers, ensuring compliance with specifications, analytical methods, and quality control parameters as required by Thailand’s Ministry of Public Health.
  • Export Authorization to Thailand: With this certification, Taj Pharma is officially permitted to export Oral Solid Dosage and External Preparations into Thailand’s regulated market, providing confidence to local importers, hospitals, and pharmacies.
  • Alignment with ASEAN Harmonization Goals: Our compliance with Thailand FDA-GMP also paves the way for easier registration and distribution across other ASEAN member nations through the ASEAN Mutual Recognition Arrangement (MRA) for GMP inspections.

By securing FDA Thai certification, Taj Pharma not only confirms its technical competence and product reliability but also establishes a robust foothold in one of Asia’s most quality-conscious and fast-growing pharmaceutical markets.

This provides our global clients assurance of non-redundant audits, smooth registration processes, and reduced timelines for product launches across regulated territories.

EU-GMP Certification: The Gold Standard of Pharmaceutical Excellence

Compliance with EU-GMP (European Union Good Manufacturing Practice), overseen by authorities like BfArM and ANSM, confirms that our plant:

  • Operates high-class HVAC and cleanroom systems
  • Maintains cleaning validation and traceability protocols
  • Follows product serialization, GDP, and data integrity standards
  • Performs real-time stability monitoring and batch control

With EU-GMP certification, our plant becomes eligible for centralized marketing authorization, mutual recognition, and EU-wide distribution.

EU-GMP Certification: The Gold Standard of Pharmaceutical Excellence

In today’s highly regulated pharmaceutical environment, EU-GMP (European Union – Good Manufacturing Practice) stands as the ultimate benchmark for quality, safety, and operational excellence. At Taj Pharma’s OSD & External Preparations Plant, EU-GMP certification not only validates our commitment to producing world-class medications—it also enables seamless access to some of the most tightly controlled markets in the world, including the entire European Union.

This certification, governed by authoritative bodies such as Germany’s BfArM (Federal Institute for Drugs and Medical Devices) and France’s ANSM (National Agency for the Safety of Medicines and Health Products), reflects our readiness to manufacture products that meet EU-level regulatory, clinical, and operational expectations. It is not merely a badge of compliance—it is a strategic enabler of global growth.


State-of-the-Art HVAC and Cleanroom Systems

One of the core pillars of EU-GMP compliance is environmental control. Our manufacturing infrastructure integrates high-performance HVAC (Heating, Ventilation, and Air Conditioning) and GMP-classified cleanrooms, ensuring the tightest levels of air purity, temperature, humidity, and pressure.

  • HEPA filtration maintains sterile zones for sensitive processes.
  • Laminar airflow in critical areas minimizes cross-contamination risk.
  • Temperature and RH (Relative Humidity) monitoring is conducted via automated, calibrated systems.
  • Differential pressure systems separate production zones by cleanliness classification (Grade A, B, C, D).
  • Dynamic airlocks and pass-throughs regulate material and personnel movement to eliminate contamination ingress.

These systems are continuously monitored and validated, ensuring that every batch is produced in a controlled, sterile, and compliant environment—critical for both oral solid dosage and external/topical preparations.


Validated Cleaning Procedures and Traceability Protocols

Cleanliness is non-negotiable in EU-GMP environments. Our plant implements fully validated cleaning procedures, supported by a structured cleaning validation master plan (CVMP) to prevent cross-contamination.

  • Each piece of equipment undergoes cleaning validation using swab and rinse sampling techniques.
  • Limits for residual active ingredients and cleaning agents are scientifically defined and routinely verified.
  • Cleaning frequencies are defined by usage patterns, with full documentation and periodic revalidation.

Alongside cleaning, our traceability framework allows full product tracking across the supply chain:

  • Electronic Batch Manufacturing Records (eBMR) provide real-time status and audit trails.
  • Material flow mapping ensures raw materials, intermediates, and finished goods are fully traceable.
  • Barcoding and digital serialization systems track every product unit from production to distribution.

This end-to-end traceability ensures accountability, batch recall efficiency, and full transparency in line with European expectations.


Serialization, GDP Compliance, and Data Integrity

With the introduction of the EU Falsified Medicines Directive (FMD), serialization has become a mandatory requirement for pharmaceutical manufacturers entering the European market. Taj Pharma’s plant has implemented:

  • 2D barcodes and unique identification codes on every saleable pack.
  • Tamper-evident features to protect package integrity.
  • Real-time data synchronization with the European Medicines Verification System (EMVS).

In addition to serialization, we follow strict Good Distribution Practices (GDP), ensuring:

  • Cold chain monitoring, where required.
  • Qualified shipping vendors and storage partners.
  • Standard operating procedures for transportation, labeling, and returns.

Our IT systems are fully 21 CFR Part 11 and Annex 11 compliant, built around ALCOA+ principles of data integrity—Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available. Every process step, from batch preparation to QC release, is digitally logged and reviewed, ensuring total compliance and audit readiness.


Real-Time Stability Monitoring and Robust Batch Control

To maintain EU-GMP status, a product must remain stable, safe, and effective throughout its shelf life. Our plant carries out ICH-compliant stability studies (Q1A–Q1F), simulating Zone II, Zone IVa, and Zone IVb storage conditions to reflect export markets in Europe, Southeast Asia, Latin America, and the Middle East.

  • Real-time and accelerated stability testing is performed using fully validated chambers with electronic monitoring.
  • Stability-indicating assays evaluate product degradation and impurity formation over time.
  • Trend analysis informs expiry date setting and out-of-specification (OOS) investigations.

For each manufactured batch:

  • In-process quality checks (IPQC) validate every critical control point.
  • Finished product testing is performed in our NABL-accredited lab.
  • Batch Release is authorized by Qualified Persons (QPs) trained in EU-GMP regulations.

This structured approach ensures every batch is not only regulatory compliant, but also therapeutically reliable when it reaches the patient.


Strategic Advantage: Centralized Authorization and EU-Wide Access

EU-GMP certification is more than just a compliance milestone—it unlocks an array of strategic opportunities for Taj Pharma:

  • Eligibility for Centralized Marketing Authorization (MA) via the European Medicines Agency (EMA), which grants access to all EU and EEA member states through a single regulatory process.
  • Use of Mutual Recognition Procedure (MRP) or Decentralized Procedure (DCP) to register the same product across multiple EU territories without duplicating clinical or technical submissions.
  • Greater acceptance in PIC/S and other regulated markets, including Australia, Canada, and South Korea, which recognize EU-GMP as equivalent or superior.

This capability positions us as a preferred manufacturing partner for global brands, licensors, and government health bodies seeking a compliant, reliable, and cost-effective production base.


EU-GMP as a Catalyst for Global Growth

Our compliance with EU-GMP guidelines marks a pivotal achievement in Taj Pharma’s journey as a global pharmaceutical leader. It reflects our dedication to precision, accountability, and patient safety, embedded into every aspect of our manufacturing operation.

By aligning with EU-GMP, we don’t just meet regulatory requirements—we deliver confidence to regulators, quality to healthcare providers, and trust to patients around the world. It is this foundation that enables us to expand seamlessly into regulated and semi-regulated markets with products that meet the highest global standards.

Market-Specific Certifications: Tailored for Strategic Regions

ANVISA (Brazil)

Our plant is ANVISA-inspected, authorizing export to Brazil. This involves:

  • Plant inspections by ANVISA regulators
  • Comprehensive dossier submission
  • Product-specific GMP audits

The scrutiny is high, especially for OSD generics, where analytical validation, dissolution profiling, and batch reproducibility are critical.

Market-Specific Certifications: Tailored for Strategic Regions

ANVISA (Brazil): Gateway to Latin America’s Largest Pharmaceutical Market

Securing ANVISA (Agência Nacional de Vigilância Sanitária) approval is a testament to a pharmaceutical plant’s regulatory maturity and global competitiveness. Taj Pharma’s OSD and External Preparations facility is ANVISA-inspected and approved, making it fully authorized to manufacture and export pharmaceutical products to Brazil, one of the most regulated and commercially significant markets in Latin America.

This certification process is rigorous, multi-staged, and product-specific, ensuring that only facilities meeting Brazil’s stringent regulatory expectations are permitted to supply its public and private healthcare systems.


In-Depth ANVISA Plant Inspections

Unlike many international regulators, ANVISA mandates in-person, on-site audits of pharmaceutical manufacturing facilities prior to granting GMP certification. These inspections evaluate:

  • Production flow and layout for material and personnel movement to minimize contamination risk.
  • Environmental controls, including HVAC validation and microbial control measures.
  • Documentation systems, SOP implementation, and adherence to cGMP principles.
  • Cleaning and changeover procedures, especially for multi-product facilities.
  • Quality assurance systems, including deviation control, CAPA management, and internal audit processes.

Our facility has successfully undergone this audit, demonstrating full readiness for commercial supply to Brazil, including for high-sensitivity molecules and chronic therapy OSDs.


Comprehensive Dossier Submission & Regulatory Filing

ANVISA approval also depends on the dossier quality—a critical element in securing product registration. We provide:

  • Complete CTD-format registration dossiers, covering Modules 1 through 5.
  • Full analytical method validation data, as per Brazilian Pharmacopoeia and ICH guidelines.
  • In-vitro bioequivalence and dissolution profile studies, with comparative results vs. Brazilian reference products.
  • Stability data in line with ICH Zone IVb conditions, simulating Brazil’s tropical climate.

This robust documentation enables both product registration and pre-approval inspections, expediting the process of entering Brazil’s regulated pharmaceutical market.


Product-Specific GMP Audits: Focused and Technical

For certain categories—especially oral solid dosage forms (OSDs), antimicrobials, and hormonal preparations—ANVISA may conduct product-specific GMP audits. These are technically deep and focus on:

  • Consistency and reproducibility of manufacturing processes across three or more consecutive validation batches.
  • Analytical method transfer and validation reports, ensuring lab reproducibility.
  • Dissolution and disintegration profiles across multiple batches and shelf life stages.
  • Packaging system compatibility, especially for tropical storage zones.
  • Raw material traceability and supplier qualification audits.

Taj Pharma’s facility complies with these stringent audit expectations, including routine quality reviews, trending analysis, and deviation root cause evaluations, all maintained in Portuguese-translated formats where required.


Strategic Advantage of ANVISA Certification

Having ANVISA approval enables us to:

  • Access one of the world’s largest emerging markets with over 210 million people and a $30+ billion pharmaceutical economy.
  • Partner with Brazilian distributors and licensees seeking high-quality generics from pre-approved global facilities.
  • Expand into other Latin American markets—such as Argentina, Colombia, and Peru—that often view ANVISA approval as a benchmark for quality.
  • Participate in government tenders and public procurement programs in Brazil, where ANVISA approval is mandatory.

Localized Compliance, Global Reach

ANVISA certification isn’t just about market entry—it’s about proving that we can meet one of the world’s most complex and localized regulatory frameworks. With our Brazil-ready plant and dossier expertise, Taj Pharma stands uniquely positioned to supply quality-assured, therapeutically effective, and economically viable products to Brazil and beyond.

Our commitment to country-specific regulatory excellence is what enables us to grow in strategic geographies with confidence and compliance.

COFEPRIS (Mexico), INVIMA (Colombia), SFDA (Saudi Arabia), GCC-DR (Gulf Cooperation Council)

We hold certifications or approvals from:

  • COFEPRIS: Validates consistent production of generics and ensures CTD dossier compliance
  • INVIMA: Mandates GMP conformity for both external and oral forms
  • SFDA: Requires packaging compliance, product labeling, and analytical validations
  • GCC-DR: Enables unified registration for Saudi Arabia, UAE, Bahrain, Qatar, Oman, and Kuwait under GMP harmonization and analytical scrutiny

Each of these certifications confirms our readiness for regional audits, BE data submission, and localized labeling protocols.

Strategic Regulatory Certifications: COFEPRIS, INVIMA, SFDA, and GCC-DR Compliance

To support global market expansion and ensure seamless product registrations, Taj Pharma’s Oral Solid Dosage (OSD) and External Preparations Plant complies with a wide spectrum of market-specific regulatory certifications. Our facility’s infrastructure, documentation systems, and quality assurance protocols are built to meet and exceed the stringent expectations of international regulatory bodies such as COFEPRIS (Mexico), INVIMA (Colombia), SFDA (Saudi Arabia), and GCC-DR (Gulf Cooperation Council Drug Regulatory Authority).

These certifications collectively serve as powerful enablers for market access across Latin America, the Middle East, and the Gulf—regions where pharmaceutical oversight is becoming increasingly harmonized with global best practices.


COFEPRIS (Mexico): Regulatory Backbone of North Latin America

COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) is the central authority regulating pharmaceuticals in Mexico. To maintain approval for Mexican market entry, our plant adheres to:

  • Consistent GMP-compliant manufacturing of generics, with full batch reproducibility.
  • Validation of analytical methods, meeting Mexican Pharmacopoeia standards.
  • Comprehensive CTD (Common Technical Document) dossier submissions, fully aligned with ICH guidelines.
  • Microbial and stability data, especially critical for external preparations in hot and humid zones.

Our compliance with COFEPRIS inspection protocols and dossier scrutiny processes ensures that all submissions are audit-ready, while enabling direct partnerships with Mexican distributors and government healthcare procurement channels.


INVIMA (Colombia): Full GMP Oversight for OSD and External Preparations

INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) is Colombia’s pharmaceutical authority, recognized for its stringent approach to Good Manufacturing Practice enforcement and technical documentation assessment.

Key INVIMA requirements our plant fulfills include:

  • Comprehensive GMP conformity, with site inspection readiness and validated processes for both oral solids and topical formulations.
  • Full CTD format submission, including risk-based product development reports, manufacturing narratives, and cleaning validation.
  • Pre-approval sample testing, where INVIMA may request finished product samples for analytical verification.
  • Product classification, labeling, and monograph alignment with Colombia’s Ministry of Health standards.

With INVIMA compliance, we serve as a reliable partner for Andean region drug supply, extending our reach into Ecuador, Peru, Bolivia, and Chile, which often accept INVIMA-registered dossiers through bilateral recognition agreements.


SFDA (Saudi Arabia): Gold-Tier Regulatory Compliance in the Middle East

The Saudi Food and Drug Authority (SFDA) is one of the most rigorous regulatory bodies in the MENA region. Our facility has been approved to meet SFDA’s demanding framework, which includes:

  • GMP compliance audits, with specific emphasis on HVAC qualification, controlled environments, and hygiene zones.
  • Product-specific dossier reviews, with thorough analytical method validation and pharmacopoeial conformance.
  • Arabic and English labeling, patient information leaflets (PIL), and packaging validation per Saudi standards.
  • Packaging material controls, including compatibility, integrity, and anti-counterfeiting features.

For Saudi Arabia, product registration also mandates stability testing in Zone IVb, submission of bioequivalence (BE) data for generics, and batch release testing through SFDA-approved laboratories, all of which our plant is fully equipped to handle.


GCC-DR (Gulf Cooperation Council – Drug Regulatory Authority): One Certificate, Six Markets

The GCC-DR streamlines pharmaceutical registration across six key Gulf countries: Saudi Arabia, United Arab Emirates (UAE), Bahrain, Kuwait, Qatar, and Oman. Our plant’s approval by GCC-DR reflects our adherence to:

  • Harmonized GMP standards, based on EMA, ICH, and WHO frameworks.
  • Analytical and dossier scrutiny, conducted by member nation authorities under a centralized review process.
  • Unified CTD submission, with modules tailored to reflect localized expectations, including Arabic translations.
  • Shared audit observations, allowing one country’s GMP inspection to satisfy others under mutual recognition.

Through GCC-DR certification, Taj Pharma is positioned to rapidly register and distribute across the entire Gulf region, eliminating regulatory redundancies and reducing time-to-market.


Cross-Regional Compliance: The Engine for Scalable Export Growth

All four regulatory bodies—COFEPRIS, INVIMA, SFDA, and GCC-DR—demand a high level of documentation rigor, data transparency, and quality control maturity. Taj Pharma’s OSD and External Preparations Plant complies with:

  • Real-time stability monitoring, with ICH Zone IVa/b protocols.
  • Bioequivalence study submissions, conducted via approved CROs in compliance with GCP guidelines.
  • Customized artwork and multilingual labeling, as per local health authority formats.
  • Active pharmacovigilance reporting systems, as mandated by SFDA and GCC authorities.

Compliance That Builds Confidence Across Continents

Taj Pharma’s approach to regulatory certification goes far beyond mere box-checking. Our facility’s alignment with COFEPRIS, INVIMA, SFDA, and GCC-DR standards is an intentional strategy to embed trust, transparency, and technical credibility into every aspect of our manufacturing operations.

This multi-market readiness allows us to serve millions of patients across Latin America and the Middle East with products that meet global safety, efficacy, and quality benchmarks—backed by local compliance every step of the way.

ISO Certifications: Ensuring Operational, Environmental, and Occupational Excellence

ISO 9001:2015 – Quality Management System

Our ISO 9001:2015 certification validates our enterprise-wide quality culture, ensuring:

  • End-to-end process consistency
  • Structured risk-based thinking
  • Systematic deviation handling
  • Customer satisfaction monitoring

ISO 14001 – Environmental Compliance

We are committed to sustainable manufacturing through ISO 14001, focusing on:

  • Zero-discharge effluent treatment
  • VOC capture in external preparation lines
  • Green energy initiatives within plant operations

ISO 45001 / OHSAS 18001 – Health and Safety

Employee safety is non-negotiable. Our plant maintains:

  • Real-time incident tracking
  • Risk mitigation assessments
  • Compliance with occupational health regulations

This protects technicians, QA/QC analysts, R&D staff, and all stakeholders involved in plant operations.

National Regulatory Licenses: Legal Backbone for Manufacturing

Drug Manufacturing License (CDSCO India)

Our licenses include:

  • Form 25: For general tablets, capsules, and powders
  • Form 28: For antibiotic and non-antibiotic creams, gels, ointments

Both licenses are renewed under CDSCO protocols and comply with Indian Drug & Cosmetics Act.

Pollution Control Board (CPCB/SPCB) NOC

We maintain valid environmental clearances by demonstrating:

  • Fully functional ETP
  • Waste segregation systems
  • Air emission control (Particulate + VOCs)

NABL Accreditation: Laboratory Credibility for Global Clients

Our in-house Quality Control laboratories are NABL-accredited under ISO/IEC 17025, proving:

  • Precision testing of raw materials, APIs, and finished products
  • Validated HPLC, UV, FTIR, and stability chambers
  • Calibration traceability to international standards

Bioequivalence Studies: Clinical Proof of Therapeutic Efficacy

We perform Bioequivalence (BE) studies through audited CROs, covering:

  • Crossover design trials in healthy volunteers
  • Validated PK/PD data collection
  • Submission-ready BE reports for ANDA and DCP filings

BE is mandatory for OSD products entering USFDA, EMA, ANVISA, and SFDA markets.

External Preparations – Unique Compliance Requirements

Microbiological and Stability Validation

External dosage forms undergo:

  • Preservative efficacy testing (PET)
  • Microbial Limit Tests (MLT)
  • Accelerated and real-time stability in Zone IVa/IVb

Packaging Validation and Compatibility

All topical dosage forms are subject to:

  • Leachability testing (for aluminum and laminated tubes)
  • Closure integrity testing
  • Container–content interaction studies

This guarantees that packaging remains non-reactive, protective, and patient-friendly in humid climates and long supply chains.

Ongoing Compliance Systems: The Backbone of Regulatory Readiness

Our plant sustains all certifications through a digitally integrated compliance model, including:

  • Annual Product Quality Reviews (APQR)
  • Deviation and CAPA Management
  • Ongoing GMP refresher training
  • Change control logs
  • Internal audits and mock inspections

These systems ensure that regulatory audits, whether pre-scheduled or surprise, are passed with confidence.

The Taj Pharma Edge in Global Regulatory Integration

Taj Pharma’s OSD and External Preparations Plant represents a unified framework of internationally benchmarked certifications, quality-first manufacturing, and regulatory alignment. Whether targeting regulated markets (EU, US, Brazil) or semi-regulated economies (MENA, LATAM, Southeast Asia), we are equipped to deliver quality pharmaceutical products, backed by globally accepted standards.

Through consistent investment in compliance, certifications, and capabilities, we continue to emerge as a preferred contract manufacturing and export partner for pharmaceutical companies across continents.